EP Patent

EP1808431A1 — Mutilin derivatives and their use as pharmaceutical

Assigned to Nabriva Therapeutics AG · Expires 2007-07-18 · 19y expired

What this patent protects

14-O-[(((C 1-6 )Alkoxy-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[(((C 1-6 )Alkylthio-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[(((C 1-6 )Mono- or dialkylamino-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins. 14-O-[((Hydroxy-(C 1-6 )-alkyl)-phenylsulfanyl…

USPTO Abstract

14-O-[(((C 1-6 )Alkoxy-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[(((C 1-6 )Alkylthio-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[(((C 1-6 )Mono- or dialkylamino-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins. 14-O-[((Hydroxy-(C 1-6 )-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C 0-5 )-alkyl)-phenylsulfanyl)-acetyl]-mutilins,14-O-[((Guanidino-imino-(C 1 - e )alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C 1-6 )alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C 1-6 )alkyl)-phenylsulfanyl)-acety]-mutilins, 14-O-[((Isothioureido-imino-(C 1-6 )alkyl)-ph enylsulfanyl)-acetyl]-mutilins, 14-O-[(((C 1-8 )Alkoxy-(C 1-6 )alkyl)- 5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C 1-6 )-alkyl)-5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C 0-6 )-alkyl)- 5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[((Guanidino-imino-(C 1-6 )alkyl)- 5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[(C 1-6 )Alkylguanidino-imino-(C 1-6 )alkyl)-5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C 1-8 )alkyl)- 5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[Thioureido-imino-(C 1-6 )alkyl)- 5- or 6-membered heteroarylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C 1-6 )alkyl)- 5-or 6-membered heteroarylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.

Drugs covered by this patent

Patent Metadata

Patent number
EP1808431A1
Jurisdiction
EP
Classification
—
Expires
2007-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Nabriva Therapeutics AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.